RBC Capital Reiterates Outperform on Surgery Partners, Maintains $19 Price Target

RBC Capital analyst Ben Hendrix has reiterated an 'Outperform' rating on Surgery Partners (NASDAQ: SGRY) while maintaining a price target of $19. This endorsement reflects confidence in the company's performance and potential for growth in the market.